Your browser doesn't support javascript.
loading
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
McNamara, Ryan P; Maron, Jenny S; Boucau, Julie; Roy, Vicky; Webb, Nicholas E; Bertera, Harry L; Barczak, Amy K; Positives Study Staff, The; Franko, Nicholas; Logue, Jennifer K; Kemp, Megan; Li, Jonathan Z; Zhou, Ling; Hsieh, Ching-Lin; McLellan, Jason S; Siedner, Mark J; Seaman, Michael S; Lemieux, Jacob E; Chu, Helen Y; Alter, Galit.
Afiliação
  • McNamara RP; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Maron JS; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Boucau J; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Roy V; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Webb NE; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Bertera HL; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Barczak AK; Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
  • Positives Study Staff T; Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
  • Franko N; Harvard Medical School , Boston, Massachusetts, USA.
  • Logue JK; Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
  • Kemp M; Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts, USA.
  • Li JZ; Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
  • Zhou L; Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
  • Hsieh CL; Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
  • McLellan JS; Harvard Medical School , Boston, Massachusetts, USA.
  • Siedner MJ; Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts, USA.
  • Seaman MS; Department of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.
  • Lemieux JE; Department of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.
  • Chu HY; Department of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.
  • Alter G; Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
mBio ; 14(4): e0090223, 2023 08 31.
Article em En | MEDLINE | ID: mdl-37535402
While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2-3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos